Should you Buy Pfizer Stock?

PUBLISHED Jul 8, 2024, 10:58:30 PM        SHARE

img
imgNoah Brody

Should you Buy Pfizer Stock?

About Pfizer Inc. (PFE)

Pfizer Inc. is an American pharmaceutical company founded in 1849 and headquartered in New York, New York. They specialize in the development and research of medicines and vaccines, notably the Pfizer-BioNTech Covid-19 vaccine. Other medications, from treatments to reduce blood clots, to treatments for breast cancer, make up a large portion of their annual revenue.

With Covid vaccine sales lowering in the past few years, revenue has struggled to reach the peaks achieved in the peak of the pandemic. After reaching all-time highs of nearly $60 per share, the stock price for Pfizer has struggled. In the past full year, Pfizer stock has dropped over 25%, falling to the current price of $27.60.

The free-cash-flow based intrinsic value model for Pfizer by GuruFocus paints a more positive picture, however. Based on their formula, Pfizer’s intrinsic value is $53.65, far surpassing the current price of $27.60. Additionally, their price-to-projected-FCF is better than 92% of companies in the drug manufacturing sector. This is exceptional, and indicates that the market might be undervaluing Pfizer stock.

Is Pfizer Worth Watching?

Based on the intrinsic value, I would already feel comfortable saying that Pfizer stock is worth considering. Recent stock performance appears to suggest that the market as a whole is more cautious. There are certainly concerns from potential investors. Lesser demand for Covid vaccines has dampened expectations, and lower revenues have been a concern. Pfizer’s Q1 earnings report showed a 20% decrease in revenue when compared to 2023.

This year, Pfizer projects approximate revenue of $61.5 billion, which would be an increase of 3% to 4% versus 2023, and have introduced cost-saving measures that should also positively impact profitability. There is positivity on the horizon, however. Positive signs on new cancer treatment drugs Adcetris and Lorbrena indicate that they may gain FDA approval, which could provide tremendous value for investors. With this being said, I believe Pfizer is a stock worth considering.

The Last Couple of Years Have Been Rough

Following the success of their stock following the Covid-19 vaccine and release of Paxlovid, Pfizer stock rose to an all-time high of $55.05 in 2021. Since the decline in frequency of Covid cases, there has been a gradual decline in the stock price of Covid, as Pfizer revenues took a sharp downturn.

This decrease in stock price is common among healthcare companies following Covid, but appears to have impacted those companies who produced Covid-19 vaccines more than others. Moderna, who reached an all-time high of $484 in 2021, now trades at $133.18. These were the first two vaccines to make it to market, and both have struggled to regain their positive stock performance since the end of the pandemic.

There’s a Bright Future Ahead

Despite recent struggles with their stock’s performance, there is reason to be optimistic with the future of Pfizer’s stock. The acquisition of Seagen, a cancer drug manufacturer, in 2023 offers potential to right the ship. The previously mentioned Adcetris and Lorbrena have the potential to provide long-term value, and not just with a one-time opportunity like we saw with the Covid-19 pandemic. These reliable, longer-term projects provide more value to investors, as there will be greater potential for more revenue over a longer period of time.

In addition to their acquisition of Seagen, the research and development at Pfizer offers promising signs with drugs in trial. They currently have 37 different drugs in late-stage trials, as well as 28 in the mid-stages. These factors all combine to highlight Pfizer’s lofty, but not unreasonable, goals. Their plan is to release a further 8 cancer treatments to hit the market by 2030. They anticipate this to reach a total of 4.6 million patients, doubling the current number being treated by their medications currently.

As a result of these drugs, Pfizer anticipates these drugs to add approximately $45 billion to their annual revenue by 2030. To put that into perspective, their revenue for 2023 was $58.5 billion. They do feel that they have a plan for success, and that has created optimism for some investors as well. One other factor that some have pointed to as a key source of value is Pfizer’s very strong dividend. The annual yield is 6.07% with quarterly dividends of $0.42. This comes at the heels of 15 years of increasing their dividend.

Is Pfizer a Buy or Sell?

While many investors see tremendous value in Pfizer, others wonder if it is a value trap. The investments made during Covid have not caused increases that their peers have seen, and resulted in the spending of tens of billions of dollars. Many are optimistic that the recent moves to diversify their non-Covid lineup will lead to more sustainable performance in the future.

These non-Covid medications have also been performing better than projected. Pfizer reported 11% operational sales growth in Q1 for these non-Covid drugs. This is expected to preceded mid-single-digit increases through 2025 when patent losses could impact these numbers.

The largest source of optimism for Pfizer, however, is certainly their cancer treatment focus. The acquisition of Seagen sent a clear message that their goal is to invest heavily into research and development of new cancer treatments, and some investors are taking notice. There is possibility for tremendous value with Pfizer, as the stock is currently already undervalued according to their intrinsic value even before these new treatments have finished their clinical testing. It is for these reasons that I believe Pfizer strongly warrants consideration as a buy for investors.

PFE, Buy

Pfizer Inc
Return: -5.88%

PFE, Buy

Return: -5.88%


Sound investments
don't happen alone

Find your crew, build teams, compete in VS MODE, and identify investment trends in our evergrowing investment ecosystem. You aren't on an island anymore, and our community is here to help you make informed decisions in a complex world.

More Reads
Which is the Better Buy? Gilead Sciences vs Bristol-Myers Squibb
Image

Gilead Sciences and Bristol-Myers Squibb are both major pharmaceutical companies, but which of the two is a better opportunity?

Is Eli Lilly Co. a Buy?
Image

They are one of the largest healthcare companies in the world, but should you buy Eli Lilly Co.?

Is AbbVie Stock a Buy?
Image

AbbVie is one of the largest pharmaceutical companies in the world, but should you buy?

CVS Health (Aetna Inc.) vs Cigna Group
Image

Which health insurance company is a better buy opportunity?

Expecting A Dip
Image

Stock Market Commentary

Differentiators
Image

How Stockbossup is different

If anyone listened they got a huge gain
Image

I have a post for 8/20/2022

Is Healthcare a Good Investment Right Now?
Image

Taking a deep dive into the healthcare sector to determine if it is a good time to buy!

Medtronic Vs Stryker: Which is a Better Buy?
Image

Which of these two major players in the medical device sector is a better buy?

What Materials Should I Invest in?
Image

The materials sector has a wide range of options for different investment strategies. From the speculative nature of rare earth elements to the income strategies around timber production, an investor looking through material stocks has a lot of directions to go.

What will the Metaverse be in five years?
Image

The metaverse is here to stay as the next iteration of the internet. While an older generation may not see why this is the next technology, a younger generation and their parents are seeing the transition.

Virtual Events in the Metaverse
Image

People are more than ever going to live events, but virtual events are seeing an uptick in 2024. With new ad revenue streams in works, virtual events could see a new resurgence.

Metaverse ETFs
Image

While the Metaverse megatrend is looking promising in 2024, the collapse in metaverse investments prices in 2021 and 2022 caused at least three metaverse themed ETFs to liquidate.

Microsoft and the Growth Explosion
Image

Microsoft is an amazing stock for new investors to try. The company has evolved, acquired, and developed a multifaceted set of businesses that are fundamentally driving growth. But for new investors, the barrier to entry is mindset.

AGCO Group - The Pure-Play Farming Stock May be too Hot!
Image

The stock’s intrinsic value clearly shows the cyclicality of the farming industry, independent of AGCO’s own analysis. Agco’s analysis also takes into account the farming industry cyclicality.

Littelfuse - Undervalued Opportunity to Hold for Years
Image

Littelfuse (LFUS) is a component manufacturer currently near a $6 Billion market capitalization. This makes it a small-cap stock, with the potential for further growth in its market segments or to be bought out by a competitor.

Dover Corporation - Great Dividend Stock but Possibly Overpriced
Image

Dover Corporation is a strong investment candidate thanks to its consistent dividend growth, its robust financial performance, and strong capital implementation plan. This stock fits into a strong dividend portfolio well that plans on holding onto stocks for multiple years.

Is BorgWarner a Buy?
Image

BorgWarner fell below $30 today, making it an interesting buy opportunity. The reasons are quite straightforward. The company’s book value per share is $25.36 a share. This means that as long as money continues to be made, BorgWarner becomes undervalued if it nears its book value per share.

Union Pacific is Going Nowhere
Image

Union Pacific is not a buy to start off 2024. Union Pacific is a fine business. There are issues but nothing that is significant enough to believe the company’s intrinsic value will shrink in the next decade.

Resources for Publishers
Resources for New Investors
Boosted with BossCoin
Financial Literacy Leaders
user_profile
Wise Intelligent
user_profile
Tom Hamilton
user_profile
Mark Robertson
user_profile
Kevin Matthews II
user_profile
Akeiva Ellis
user_profile
Brendan Dale
user_profile
Kenneth Chavis IV
user_profile
Sharita Humphrey